Publications by authors named "Annabelle Monnet"

Claim this Profile
A
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Gennaro Pagano, Dylan Trundell, Tanya Simuni, Nicola Pavese, Kenneth Marek, Annabelle Monnet

NPJ Parkinsons Dis· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Gennaro Pagano, Dylan Trundell, Tanya Simuni, Nicola Pavese, Kenneth Marek, Annabelle Monnet

NPJ Parkinsons Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Kirsten I Taylor, Florian Lipsmeier, Marzia A Scelsi, Ekaterina Volkova-Volkmar, Daria Rukina, Annabelle Monnet

NPJ Digit Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.
Tania Nikolcheva, Gennaro Pagano, Nathalie Pross, Tanya Simuni, Kenneth Marek, Annabelle Monnet

Parkinsonism Relat Disord· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III.
Dylan Trundell, Evan W Davies, Louise Barrett, Stefano Zanigni, Nima Shariati, Annabelle Monnet

J Parkinsons Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.
Gennaro Pagano, Annabelle Monnet, Adriana Reyes, Benjamin Ribba, Hanno Svoboda

Nat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling of Parkinson's Disease Progression and Implications for Detection of Disease Modification in Treatment Trials.
Benjamin Ribba, Tanya Simuni, Kenneth Marek, Andrew Siderowf, Cheikh Diack, Annabelle Monnet

J Parkinsons Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.
Gennaro Pagano, Kirsten I Taylor, Judith Anzures Cabrera, Tanya Simuni, Kenneth Marek, Annabelle Monnet

Nat Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Gennaro Pagano, Kirsten I Taylor, Judith Anzures-Cabrera, Maddalena Marchesi, Tanya Simuni, Annabelle Monnet

N Engl J Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
Karen Yee, Cristina Papayannidis, Norbert Vey, Michael J Dickinson, Kevin R Kelly, Annabelle Monnet

Leuk Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia.
Pau Montesinos, Benjamin M Beckermann, Olivier Catalani, Jordi Esteve, Katia Gamel, Annabelle Monnet

Future Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion-With an application to the design of a clinical trial in acute myeloid leukemia.
Kaspar Rufibach, Dominik Heinzmann, Annabelle Monnet

Pharm Stat· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
Sai-Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, Ramaswamy Govindan, James Chih-Hsin Yang, Annabelle Monnet

J Clin Oncol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis